VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with a Ki value of 104 pM. VTP50469 has anti-leukemia activity.

 

Brand: BCM

 

Target: Menin-MLL interaction(ki):ki:104 pM

 

Signaling Pathways: Apoptosis; Chromatin/Epigenetic

 

In Vivo: In NSG mice, VTP50469 (15-60 mg/kg; p.o.; twice a day; for 28 days) treatment is highly efficacious across all dosage levels and all treatment groups have a significant survival advantage. Mice dosed at 30 and 60 mg/kg VTP50469 extends survival advantage.

 

Boiling Point: 735.2±70.0 °C(Predicted)

 

pKa: 10.97±0.40(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

Isomeric SMILES: CC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)C  

 

InChIKey: ADHHOUXZPBYYSU-UHFFFAOYSA-N  

 

InChI: InChI=1S/C32H47FN6O4S/c1-22(2)39(23(3)4)31(40)27-16-25(33)8-11-28(27)43-29-17-34-21-35-30(29)38-19-32(20-38)12-14-37(15-13-32)18-24-6-9-26(10-7-24)36-44(5,41)42/h8,11,16-17,21-24,26,36H,6-7,9-10,12-15,18-20H2,1-5H3

 

Attribute
[Chem Name]	5-fluoro-2-[4-[7-[[4-(methanesulfonamido)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide
[Synonym]	VTP50469; VTP-50469
[CAS No.]	2169916-18-9
[MDL No.]	MFCD32197139
[Formula]	C32H47FN6O4S
[Molecular]	630.82
[Form]	Solid powder
[Storage]	Stored at -20°C

Goods Tag